1. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272-82.
https://doi.org/10.1210/jc.2012-1027.
3. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
https://doi.org/10.1210/jc.2004-0952.
4. Kim HY, Ha YC, Kim TY, et al. Healthcare costs of osteoporotic fracture in Korea: information from the national health insurance claims database, 2008-2011. J Bone Metab 2017;24:125-33.
https://doi.org/10.11005/jbm.2017.24.2.125.
6. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
https://doi.org/10.1002/jbmr.253.
7. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.
https://doi.org/10.1002/jbmr.1998.
9. LeBlanc ES, Rosales AG, Black DM, et al. Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting. J Bone Miner Res 2017;32:2304-14.
https://doi.org/10.1002/jbmr.3221.
12. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50.
https://doi.org/10.1002/jbmr.1719.
13. Mahjoub Z, Jean S, Leclerc JT, et al. Incidence and characteristics of atypical femoral fractures: clinical and geometrical data. J Bone Miner Res 2016;31:767-76.
https://doi.org/10.1002/jbmr.2748.
14. Lo JC, Hui RL, Grimsrud CD, et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 2016;85:142-7.
https://doi.org/10.1016/j.bone.2016.01.002.
18. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013;28:1729-37.
https://doi.org/10.1002/jbmr.1893.
19. Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020;383:743-53.
https://doi.org/10.1056/NEJMoa1916525.
20. Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012;27:672-8.
https://doi.org/10.1002/jbmr.560.
21. Durchschlag E, Paschalis EP, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006;21:1581-90.
https://doi.org/10.1359/jbmr.060701.
22. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31.
https://doi.org/10.1016/s8756-3282(01)00414-8.
23. Tjhia CK, Odvina CV, Rao DS, et al. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011;49:1279-89.
https://doi.org/10.1016/j.bone.2011.09.042.
25. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483-92.
https://doi.org/10.1210/jc.2013-1597.
26. Selga J, Nuñez JH, Minguell J, et al. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int 2016;27:827-32.
https://doi.org/10.1007/s00198-015-3355-z.
27. Haider IT, Schneider P, Michalski A, et al. Influence of geometry on proximal femoral shaft strains: implications for atypical femoral fracture. Bone 2018;110:295-303.
https://doi.org/10.1016/j.bone.2018.02.015.
28. Silverman S, Kupperman E, Bukata S. Bisphosphonate-related atypical femoral fracture: managing a rare but serious complication. Cleve Clin J Med 2018;85:885-93.
https://doi.org/10.3949/ccjm.85a.17119.
29. Marshall RA, Mandell JC, Weaver MJ, et al. Imaging features and management of stress, atypical, and pathologic fractures. Radiographics 2018;38:2173-92.
https://doi.org/10.1148/rg.2018180073.
30. Fang C, Chau JY, Woo SB, et al. Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing: a cautionary tale from 2 cases. Geriatr Orthop Surg Rehabil 2014;5:14-7.
https://doi.org/10.1177/2151458514522058.
31. van de Laarschot DM, Smits AA, Buitendijk SK, et al. Screening for atypical femur fractures using extended femur scans by DXA. J Bone Miner Res 2017;32:1632-9.
https://doi.org/10.1002/jbmr.3164.
32. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016;31:16-35.
https://doi.org/10.1002/jbmr.2708.
36. Murphy CM, Schindeler A, Cantrill LC, et al. PTH(1-34) treatment increases bisphosphonate turnover in fracture repair in rats. J Bone Miner Res 2015;30:1022-9.
https://doi.org/10.1002/jbmr.2424.
40. Watts NB, Aggers D, McCarthy EF, et al. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res 2017;32:1027-33.
https://doi.org/10.1002/jbmr.3081.
41. Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013;52:360-5.
https://doi.org/10.1016/j.bone.2012.10.006.
42. van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the european calcified tissue society. J Clin Endocrinol Metab 2020;105:1682-99.
https://doi.org/10.1210/clinem/dgz295.
43. Ha YC, Cho MR, Park KH, et al. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 2010;468:3393-8.
https://doi.org/10.1007/s11999-010-1583-2.
46. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65.
https://doi.org/10.1210/jc.2010-1571.
47. Prasarn ML, Ahn J, Helfet DL, et al. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 2012;470:2295-301.
https://doi.org/10.1007/s11999-012-2412-6.
48. Lim HS, Kim CK, Park YS, et al. Factors associated with increased healing time in complete femoral fractures after long-term bisphosphonate therapy. J Bone Joint Surg Am 2016;98:1978-87.
https://doi.org/10.2106/jbjs.15.01422.
49. Lee KJ, Yoo JJ, Oh KJ, et al. Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: a multicenter retrospective study. Injury 2017;48:941-5.
https://doi.org/10.1016/j.injury.2017.02.036.
52. Park JH, Lee Y, Shon OJ, et al. Surgical tips of intramedullary nailing in severely bowed femurs in atypical femur fractures: simulation with 3D printed model. Injury 2016;47:1318-24.
https://doi.org/10.1016/j.injury.2016.02.026.
53. Kim JW, Kim H, Oh CW, et al. Surgical outcomes of intramedullary nailing for diaphyseal atypical femur fractures: is it safe to modify a nail entry in bowed femur? Arch Orthop Trauma Surg 2017;137:1515-22.
https://doi.org/10.1007/s00402-017-2764-1.
54. Park YC, Song HK, Zheng XL, et al. Intramedullary nailing for atypical femoral fracture with excessive anterolateral bowing. J Bone Joint Surg Am 2017;99:726-35.
https://doi.org/10.2106/jbjs.16.00760.
55. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010;47:169-80.
https://doi.org/10.1016/j.bone.2010.05.019.
57. Lee YK, Lee YJ, Lee NK, et al. Low positive predictive value of bone scan to predict impending complete fracture among incomplete atypical femoral fracture. J Korean Med Sci 2018;33:e157.
https://doi.org/10.3346/jkms.2018.33.e157.